U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 28 results

Status:
US Approved Rx (2017)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical. The drug was approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia...
Status:
US Approved Rx (2003)
First approved in 2003

Class (Stereo):
CHEMICAL (RACEMIC)



Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral. UROXATRAL (alfuzosin HCl e...
Status:
US Approved Rx (2019)
First approved in 2003

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzy...
Status:
US Approved Rx (2001)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Dutasteride is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase (5AR), intracellular enzymes that convert testosterone to 5 alpha-dihydrotestosterone (DHT). Type I 5a-...
Status:
US Approved Rx (2022)
First approved in 1997

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tamsulosin, a sulfamoylphenethylamine-derivative alpha-adrenoceptor blocker with enhanced specificity for the alpha-adrenoceptors of the prostate, is commonly used to treat benign prostatic hyperplasia (BPH). The drug is commercially available in a r...
Status:
US Approved Rx (2013)
First approved in 1992

Class (Stereo):
CHEMICAL (ABSOLUTE)



Finasteride is a synthetic 4-azasteroid compound. This drug is a competitive and specific inhibitor of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Two distinct isozymes are ...
Status:
US Approved Rx (2022)
First approved in 1990

Class (Stereo):
CHEMICAL (RACEMIC)



Doxazosin mesylate is a quinazoline compound sold by Pfizer under the brand name CARDURA. CARDURA is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms...
Status:
US Approved Rx (2000)
First approved in 1987

Class (Stereo):
CHEMICAL (RACEMIC)



Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate en...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Synthetic compound Erteberel (LY500307) is a highly potent and selective ERβ agonist; it has a 12-fold higher affinity for ERβ than ERα and exhibits 32-fold more functional potency. LY500307 was well tolerated in benign prostatic hypertrophy (BPH) pa...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Elocalcitol (also known as BXL-628), a vitamin D3 analog. This compound regulates cell proliferation and apoptosis via its binding to the vitamin D receptor (VDR) having anti-proliferative and anti-inflammatory properties in benign prostatic hyperpla...